Metastasis-related mRNAs have showed great promise as prognostic biomarkers in various types of cancers. Therefore, we attempted to develop a metastasis-associated gene signature to enhance prognostic prediction of breast cancer (BC) based on gene expression profiling. We firstly screened and identified 56 differentially expressed mRNAs by analysing BC tumour tissues with and without metastasis in the discovery cohort (GSE102484, n = 683). We then found 26 of these differentially expressed genes were associated with metastasis-free survival (MFS) in the training set (GSE20685, n = 319). A metastasis-associated gene signature built using a LASSO Cox regression model, which consisted of four mRNAs, can classify patients into high-and low-risk groups in the training cohort. Patients with high-risk scores in the training cohort had shorter MFS (hazard ratio [HR] 3.89, 95% CI 2.53-5.98; P < 0.001), disease-free survival (DFS) (HR 4.69, 2.93-7.50; P < 0.001) and overall survival (HR 4.06, 2.56-6.45; P < 0.001) than patients with low-risk scores.
medication, while others may be faced with recurrence or metastasis due to lack of appropriate treatment. 12, 13 These limitations have prompted a search for new biomarkers for discrimination of cancer patients to improve precision cancer treatment.
In recent years, detailed information regarding prognosis evaluation for cancer patients can be effectively provided by genome-wide expression profiling detection. [14] [15] [16] [17] Numerous studies have evaluated the prognostic roles of array-based gene expression signatures acquired from tumours. 14, 18, 19 Several gene signatures have also been established to distinguish the prognosis of patients beyond the BC clinicopathologic features; however, most of them are not used clinically. 17, 19, 20 Thus, identifying a novel and practical gene signature to predict patients' prognosis is urgently needed and of great clinical significance.
Several studies have identified that a number of mRNAs are differentially expressed in nasopharyngeal carcinoma, 21 lung cancer 22 and colorectal cancer 23 and so on, 24 which are associated with survival prognosis. As mRNAs related to survival are usually associated with the development and metastasis of some cancers, it is vital to develop a robust BC prognosis-related mRNAs signature. Therefore, to identify mRNAs that might serve as potentially accurate markers for predicting clinical outcome, we used the Gene Expression Omnibus (GEO) database to characterize the mRNAs profiling on large cohorts of BC patients, and finally identified a 4-mRNAs signature which can be validated.
| ME TH ODS

| Patient cohorts
To overcome the bias in microarray platforms, this study only included patients from BC-related gene expression datasets measured by the same platform (GPL570-55999, the Affymetrix HU133 Plus 2.0 microarray), including GSE102484, GSE20685, GSE21653
and GSE31448. All these gene expression and corresponding clinical data were obtained from the GEO database (https://www.ncbi.nlm.
nih.gov/geo), so the approval of ethics committee was not needed.
To evaluate the correlations of mRNAs expression with survival status for BC patients, we screened those datasets that included more than 200 patients with disease-free survival (DFS) for model development and validation in this study. In total, 1496 samples (683 from GSE102484, 319 from GSE20685, 248 from GSE21653 and 246 from GSE31448) were obtained ( Table 1 ). The GSE102484 cohort was used as the discovery cohort, and then the GSE20685 cohort was applied for the training cohort. In addition, we randomly consider GSE21653 and GSE31448 as independent external validation cohorts. A summary of these cohorts and procedures for data processing are provided in Supplementary Methods.
| Study design
| Discovery cohort
Differential mRNAs expression analysis by array was used to identify mRNAs differentially expressed in primary tumour tissues of patients with BC that have developed distance metastases or not.
To screen mRNAs expression profiles, 683 tumour samples were obtained from BC patients, which included 101 patients with distance metastasis and 582 patients without distance metastasis ( Figure 1 , Table 1 ). and X is the expression value of each mRNAs). Then, the patients were classified into high and low risk based on the optimal cut-off value of the predictor score, which was selected based on X-tile software (version 3.6.1, Yale University, CT). For the validation process, 494 patients from GSE21653 and GSE31448 were considered to evaluate the expression values of mRNAs signature respectively.
| Model development and validation cohorts
Moreover, prognostic nomogram based on mRNAs signature and clinical-related variables was plotted. In addition, patients' inclusion and exclusion criteria for training cohort and validation cohorts are showed in the Supplementary Methods.
| Statistical analysis
All the statistical analysis was performed with R software (version 
| RESULTS
| The expression of cancer metastasis-associated mRNAs in datasets through array re-annotation
Because a number of large-scale gene expression datasets are available in the GEO database, an integrative analysis of re-annotated mRNA expression datasets would provide good statistical power to capture the expression changes of mRNAs in disease condition. To avoid the inconsistency of the mRNAs expression levels on different platforms, we only collected datasets measured on the Affymetrix HU133 Plus 2.0 microarray platform to identify potential mRNAs prognostic biomarkers. After a thorough search of the GEO database, we identified three gene expression datasets with DFS time (GSE20685, GSE21653 and GSE31448). Together, these data sets include a total of 891 BC patient samples (Table 1) . Next, the corresponding mRNA expression datasets were constructed using array re-annotation analysis as described in the Methods section. Relevant clinical information including age, tumour stage (T stage), axillary lymph node stage (N stage) and DFS for the four mRNAs expression datasets are summarized in Table 1 .
| Development of survival-associated mRNAs signature for patients with BC
Samples in discovery cohort were divided into metastasis group and non-metastasis group. Fifty-six mRNAs were found to be differentially expressed between the two groups (P < 0.05, fold change Coefficients   26  25  21  11  5  0   MYBPC1  NPY1R  DEPDC1B  FLJ13744  ANLN  BUB1B  TPX2  KIF14  MCM10  TREM1  MMP1  C5orf46  KRT81  C2orf54  ST8SIA6  KRT6A  KRT80  PRAME  CRISP3  HOTAIR  THBS2  GREM1  INHBA  PLAU  KCNN2 Figure 3B ). We then did the same analyses for DFS and overall survival (OS), 5-year DFS and OS was 59.3%
and 68.7% for the high-risk group and 87.6% and 93.6% for the lowrisk group (HR: 4.69, 95% CI: 2.93-7.50, P < 0.001, Figure 3D ; HR:
4.06, 95% CI: 2.56-6.45, P < 0.001, Figure 3F ). Figure 4A ).
Similarly, in validation set GSE31448, the 5-year DFS was 57.7% for the high-risk group and 73.4% for the low-risk group (HR: 1.72, 95%
CI: 1.07-2.78; P = 0.024; Figure 4B ).
| Nomogram combined mRNAs signature and clinical-related variables predicts patients' DFS
In the training cohort, univariate and multivariate analysis all revealed that T stage, N stage and mRNAs signature were significantly associated with DFS (Table 2) . Then based on the above analysis results, we developed a mRNAs nomogram that combined the clinical-related factors (T stage and N stage) and mRNAs signature ( Figure 5A ; Table 2 ). The calibration plots for the 5-year DFS were predicted well in the training cohort, the GSE21653 validation cohorts and the GSE31448 validation cohort (
Figure 5B-E).
| DISCUSSION
An array-based database to identify survival-associated mRNAs for prognostic prediction is significant and urgently needed to guide tailored therapy for patients with BC. 20, 21, 23 In our study, we used GEO array data to screen differential mRNAs in a discovery set and Our study results show that the evaluation of four mRNAs expression could be a vital tool for the management of BC patients, which can guide the stratification of patients that may recur or metastasis, aiding in decision making for tailored therapy, and then ultimately contributing to an improvement in survival rates.
We determined a set of four mRNAs consisting of KCNN2, KRT80, GREM1 and CRISP3 that predicts DFS in three independent patient sets. KCNN2 was found to be involved in the bile secretion, and the abnormal expression of KCNN2 may be closely related to the pathogenesis of cholangiocarcinoma. 25 In addition, KCNN2 was also found under-expressed in Ewing's sarcoma family of tumours relative to alveolar rhabdomyosarcomas, and may be also involved in prostate carcinomas 26 and may increase angiogenesis, which is associated with poorer prognosis. 30 The expression of CRISP3 was associated clinical outcome in prostate cancer. 31 However, several limitations are still existed in this study as well.
First of all, our study is entirely retrospective and inherent biases may influence results. In the second place, clinical-related factors, such as molecular classification and treatment related information,
has not been analysed due to lack of relevant information in the training and validation sets. In addition, the sample size is too small and array data were all obtained from single platform, which may disturb the application of our constructed model. Last but not the least, although mRNAs signature and nomogram showed good predictive accuracy in the training cohort, their performance in the two external validation cohorts is still low and remains to be improved.
Therefore, more markers should be mined and incorporated into our prediction model in future. Calibration curves of the nomogram to predict disease-free survival at 10 years in (B) GSE20685, (C) GSE21653 and (D) GSE31448. The actual disease-free survival is plotted on the y-axis; nomogram predicted probability is plotted on the x-axis. DFS: disease-free survival
| CONCLUSION
Taken together, we filtered specific mRNAs differentially expressed between patients with or without distant metastasis and successfully constructed a prognostic associated mRNAs signature which may aid our prognosis prediction and tailored therapy for BC. Importantly, we developed a 4-mRNA nomogram that incorporated both mRNA signature and clinical-related risk factors to predict patients' prognosis. We confirmed this signature could service as potential specificity biomarkers in the prognosis prediction for BC patients.
